← All trials
NCT03513822
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 16, 2018
- Primary completion
- Oct 31, 2018
- Completion date
- Nov 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut National de la Santé Et de la Recherche Médicale, FranceLead sponsor
- University of ParisCollaborator
- Fondation ApicilCollaborator
- Hôpital Raymond PoincaréCollaborator
- CHU AMBROISE PARECollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.